Vlachakis Panayotis K, Theofilis Panagiotis, Apostolos Anastasios, Kordalis Athanasios, Sideris Skevos, Leventopoulos Georgios, Mountantonakis Stavros E, Kollias Georgios, Leontsinis Ioannis, Drakopoulou Maria, Karakasis Paschalis, Tousoulis Dimitrios, Toutouzas Konstantinos, Tsiachris Dimitrios, Gatzoulis Konstantinos, Tsioufis Costas
First Department of Cardiology, National and Kapodistrian University of Athens, School of Medicine "Hippokration" General Hospital, 114 Vasilissis Sofias avenue, Athens, 11527, Greece.
State Department of Cardiology, "Hippokration" General Hospital of Athens, Athens, Greece.
Heart Fail Rev. 2025 Mar;30(2):365-380. doi: 10.1007/s10741-024-10469-9. Epub 2024 Nov 23.
Heart failure (HF) is a major clinical challenge characterized by significant morbidity and mortality. Electrical conduction abnormalities play a critical role in HF pathophysiology and progression, often leading to suboptimal outcomes with conventional pacing techniques. Con-duction system pacing (CSP), encompassing His bundle pacing and left bundle branch area pacing, has emerged as a novel approach. Despite data come from observational studies, recent guidelines recommend that a specific population may benefit from CSP. However, significant practical considerations and challenges need to be clarified before CSP can be routinely implemented in clinical practice. The reliance on observational studies means that long-term clinical outcomes for HF patients remain uncertain until data from randomized controlled trials (RCTs) become available. Current CSP practices face challenges with lead implantation, mechanical stress on leads, and the need for more advanced tools and artificial intelligence integration to improve procedure efficacy and safety. Future large-scale RCTs are essential to identify optimal candidates and address these technical challenges, potentially leading to a paradigm shift in HF management.
心力衰竭(HF)是一项重大的临床挑战,其特征为高发病率和死亡率。心脏传导异常在HF的病理生理学和病情进展中起着关键作用,常导致传统起搏技术的效果欠佳。包括希氏束起搏和左束支区域起搏在内的传导系统起搏(CSP)已成为一种新方法。尽管数据来自观察性研究,但最近的指南建议特定人群可能从CSP中获益。然而,在CSP能够在临床实践中常规实施之前,需要澄清一些重要的实际考量因素和挑战。对观察性研究的依赖意味着,在随机对照试验(RCT)的数据可用之前,HF患者的长期临床结局仍不确定。当前的CSP实践在导线植入、导线的机械应力以及需要更先进的工具和人工智能整合以提高手术疗效和安全性方面面临挑战。未来的大规模RCT对于确定最佳候选者和解决这些技术挑战至关重要,可能会导致HF管理模式的转变。